多梳蛋SUZ12预测吉西他滨治疗肝内胆管癌疗效和预后的研究

doi:10.11904/j.issn.1002-3070.2017.04.007

实用肿瘤学杂志 ›› 2017, Vol. 31 ›› Issue (4): 321-328.doi: 10.11904/j.issn.1002-3070.2017.04.007

多梳蛋SUZ12预测吉西他滨治疗肝内胆管癌疗效和预后的研究

刘楠¹,韩志阳²,鹿芃恬¹,李丹阳¹,王英炜¹,董祥慧¹,朱宏¹

1.哈尔滨医科大学附属第一医院病理科(哈尔滨 150001);
2.哈尔滨医科大学附属第一医院普外科

收稿日期:2017-02-08 出版日期:2017-08-20 发布日期:2017-08-23
通讯作者: 朱宏,E-mail:252302504@qq.com
作者简介:刘楠,女,(1981-),博士,主治医师,从事肿瘤发病机制及预后的研究。
基金资助:
黑龙江省自然科学基金项目(H201445)

Expression of polycomb protein SUZ12 predicts poor prognosis and response of patients with intrahepatic cholangiocarcinoma to adjuvant gemcitabine-based chemotherapy

LIU Nan¹,HAN Zhiyang²,LU Pengtian¹,LI Danyang¹,WANG Yingwei¹,DONG Xianghui¹,ZHU Hong¹

1.Department of Pathology,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China;
2.Department of General Surgery,The First Affiliated Hospital of Harbin Medical University

Received:2017-02-08 Online:2017-08-20 Published:2017-08-23

摘要/Abstract

摘要： 目的本研究探讨了肝内胆管癌(ICC)患者多梳蛋白SUZ12的表达及其在预测ICC患者的生存和对治疗反应的作用。方法用免疫组织化学方法检测207个肝组织样本(包括ICC患者,胆道上皮内瘤样病变患者BilIN-1,-2,-3,和非瘤样病变的胆管样本)SUZ12和p16^INK4a蛋白的表达。评估这些蛋白的表达是否和接受化疗的ICC患者的病理学特征和生存结果相关,以及是否和随后的化疗反应相关。结果从非肿瘤性胆管组织依次到BilIN-1,-2,-3,ICC,SUZ12表达水平渐进增加。而p16^INK4a蛋白在非瘤样病变性胆管组织中大量表达,但在BilIN-1,-2,-3,ICC组织中依次逐渐降低。SUZ12表达与未分化的ICC、淋巴结转移和晚期癌症相关。Kaplan-Meier曲线分析显示,高表达SUZ12的ICC患者与低表达SUZ12的ICC患者相比,总生存期和无瘤生存期显著降低。SUZ12表达与接受吉西他滨为基础的辅助化疗(Adjuvant gemcitabine-based chemotherapy,AGC)的患者的总体存活显著相关。结论 SUZ12表达能够预测用吉西他滨为基础的化疗的ICC患者的总生存期和无病生存期。

关键词: SUZ12, 肝内胆管癌, 吉西他滨, p16^INK4a

Abstract: Objective This study explored the expression of polyclonal protein SUZ12 in patients with intrahepatic cholangiocarcinoma(ICC),and its role in predicting the survival and treatment of ICC patients.Methods The expression of SUZ12 and p16^INK4a was detected by immunohistochemical assay in 207 liver tissue samples including ICC patients,BilIN-1,-2,-3 and non-tumor-like cholangiocarcinoma.The expression of these proteins was assessed to be related to the pathological characteristics of the ICC patients receiving chemotherapy and the outcome of survival as well as the subsequent chemotherapy response.Results The expression level of SUZ12 was gradually increased from non-neoplastic bile duct tissue to BilIN-1,-2,-3 and ICC.The expression of p16^INK4a protein was expressed in non-neoplastic-like cholangiocarcinoma,but it decreased gradually in BilIN-1,-2,-3 and ICC tissues.SUZ12 expression was associated with undifferentiated ICC,lymph node metastasis and advanced cancer.Kaplan-Meier curve analysis showed that ICC patients with high expression of SUZ12 had a significant reduction in overall survival and disease-free survival in comparison with ICC patients with the low expression of SUZ12.SUZ12 expression was significantly associated with overall survival of patients receiving adjuvant gemcitabine-based chemotherapy(AGC).Conclusion SUZ12 expression is able to predict the overall survival and disease-free survival of ICC patients with adjuvant gemcitabine-based chemotherapy.

Key words: SUZ12, Intrahepatic cholangiocarcinoma, Gemcitabine, p16^INK4a

中图分类号:

R322.4

刘楠,韩志阳,鹿芃恬,李丹阳,王英炜,董祥慧,朱宏. 多梳蛋SUZ12预测吉西他滨治疗肝内胆管癌疗效和预后的研究[J]. 实用肿瘤学杂志, 2017, 31(4): 321-328.

LIU Nan ,HAN Zhiyang ,LU Pengtian ,LI Danyang ,WANG Yingwei ,DONG Xianghui ,ZHU Hong. Expression of polycomb protein SUZ12 predicts poor prognosis and response of patients with intrahepatic cholangiocarcinoma to adjuvant gemcitabine-based chemotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 321-328.

参考文献

1 Okhotnikov OI,Yakovleva MV,Pakhomov VI.Percutaneous cholangiostomy for portal cholangiocarcinoma[J].Irurgiia(Mosk),2016,9:21-27.
2 Hamano G,Kubo S,Takemura S.Comparison of clinicopathological characteristics between patients with occupational and non-occupational intrahepatic cholangiocarcinoma[J].J Hepatobiliary Pancreat Sci,2016,23(7):389-396.
3 Vijgen S,Terris B,Rubbia-Brandt L.Pathology of intrahepatic cholangiocarcinoma[J].Hepatobiliary Surg Nutr,2016,6(1):22-34.
4 Hirano S,Kondo S,Tanaka E,et al.Outcome of surgical treatment of hilar cholangiocarcinoma:a special reference to postoperative morbidity and mortality[J].J Surg Case Rep,2010,17(4):455-462.
5 Murakami Y,Uemura K,Sudo T,et al.Prognostic factors after surgical resection for intrahepatic,hilar,and distal cholangiocarcinoma[J].Ann Surg Oncol,2011,18(3):651-658.
6 Wang X,Goodrich KJ,Gooding AR.Targeting of polycomb repressive complex 2 to RNA by short repeats of consecutive guanines[J].Mol Cell,2017,65(6):1056-1067.
7 Toyokawa G,Takada K,Okamoto T.Elevated metabolic activity on ¹⁸F-FDG PET/CT is associated with the expression of EZH2 in non-small cell lung cancer[J].Anticancer Res,2017,37(3):1393-1401.
8 Eleutério J Jr,Lima TS,Cunha MD,et al.Immunohistochemical expression of the tumor suppressor protein p16^INK4a in cervical adenocarcinoma[J].Rev Bras Ginecol Obstet,2017,39(1):21-25.
9 Taniai M,Higuchi H,Burgart LJ,et al.p16^INK4a promoter mutations are frequent in primary sclerosing cholangitis(PSC)and PSC-associated cholangiocarcinoma[J].Gastroenterology,2002,123(4):1090-1098.
10 Kirmizis A,Bartley SM,Farnham PJ.Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy[J].Mol Cancer Ther,2003,2(1):113-121.
11 Cui Y,Chen J,He Z,et al.SUZ12 depletion suppresses the proliferation of gastric cancer cells[J].Cell Physiol Biochem,2013,31(6):778-784.
12 Pasini D,Bracken AP,Jensen MR,et al.Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity[J].EMBO J,2004,23(20):4061-4071.
13 Ishikawa A,Sasaki M,Sato Y,et al.Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis[J].Hum Pathol,2004,35(12):1505-1514.

[1]	吴旖琦, 刘颖, 赵丽, 金晓明. 乙肝病毒蛋白和基因在肝内和肝外胆管癌组织中的检测及意义[J]. 实用肿瘤学杂志, 2017, 31(1): 7-12.
[2]	陆颖, 黄海欣, 李桂生. GEMOX方案治疗复发或难治性非霍奇金淋巴瘤[J]. 实用肿瘤学杂志, 2011, 25(6): 547-550.
[3]	张明辉, 张清媛, 赵曙, 王小川, 马文杰, 徐珊琦, 孙妍. GP与NP方案治疗耐药晚期乳腺癌的临床观察[J]. 实用肿瘤学杂志, 2010, 24(3): 247-251.
[4]	李静, 张华. 吉西他滨联合消癌平治疗晚期非小细胞肺癌减毒增效的临床研究^△[J]. 实用肿瘤学杂志, 2009, 23(4): 307-310.
[5]	王根和, 方平, 吴怡青, 王远飞. 吉西他滨联合顺铂治疗老年晚期非小细胞肺癌研究[J]. 实用肿瘤学杂志, 2009, 23(4): 325-327.
[6]	王敏. 人乳头状瘤病毒感染、P16^INK4A及PCNA在宫颈上皮内瘤变中的意义[J]. 实用肿瘤学杂志, 2009, 23(3): 245-248.
[7]	邹丽娟, 徐晓颖, 王若雨, 邵淑娟. 吉西他滨和顺铂联合化疗对大鼠脊髓损伤的实验研究^△[J]. 实用肿瘤学杂志, 2009, 23(2): 139-141.
[8]	刘有腾;刘硕年;文军程;黄伶茜. GP方案治疗晚期非小细胞肺癌疗效观察[J]. 实用肿瘤学杂志, 2008, 22(05): 444-445.
[9]	陈静芳. 吉西他滨联合顺泊治疗晚期非小细胞肺癌的护理[J]. 实用肿瘤学杂志, 2008, 22(03): 277-278.
[10]	万一元;刘扬清;高勇;徐丽娟;刘华;易竹筠. 吉西他滨固定剂量率给药治疗31例晚期恶性肿瘤的临床观察[J]. 实用肿瘤学杂志, 2008, 22(03): 208-212.
[11]	舒阳春;刘魁凤;莫贤毅;温宗秋;陆崇. 吉西他滨联合卡铂与吉西他滨联合顺铂治疗晚期非小细胞肺癌的比较[J]. 实用肿瘤学杂志, 2008, 22(02): 101-103.
[12]	洪国标. 吉西他滨联合顺铂二线治疗晚期乳腺癌的临床观察[J]. 实用肿瘤学杂志, 2008, 22(02): 142-143.
[13]	宇静;孙秀华;张阳. GP方案和NP方案治疗晚期非小细胞肺癌疗效和不良反应比较[J]. 实用肿瘤学杂志, 2008, 22(02): 131-132,.
[14]	练祖平;侯恩存;陆运鑫;秦冰;黄丁平;刘敏;陈小梅;黄妍;关莹. 吉西他滨联合顺铂治疗晚期原发性肝癌的临床观察[J]. 实用肿瘤学杂志, 2007, 21(03): 224-225,.
[15]	井明晰;马天飞;高雅苓. 吉西他滨联合顺铂治疗复治的老年晚期非小细胞肺癌临床观察[J]. 实用肿瘤学杂志, 2007, 21(02): 137-138.

多梳蛋SUZ12预测吉西他滨治疗肝内胆管癌疗效和预后的研究

Expression of polycomb protein SUZ12 predicts poor prognosis and response of patients with intrahepatic cholangiocarcinoma to adjuvant gemcitabine-based chemotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价